Navigation Links
ADVENTRX Pharmaceuticals Announces Financing
Date:8/5/2009

odman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the exclusive placement agent for the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus supplement and accompanying base prospectus can be obtained directly from the ADVENTRX at 6725 Mesa Ridge Road, Suite 100, San Diego, California 92121 or from the SEC's website at www.sec.gov.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX's common stock will be delisted by the NYSE Amex, including as a result of failing to comply with applicable stockholder approval requirements or failing to maintain sufficient stockholders' equity or a sufficient stock price; the risk that the provisions
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
2. ADVENTRX Pharmaceuticals Announces Closing of Financing
3. ADVENTRX Pharmaceuticals Announces Financing
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
5. ADVENTRX Announces Further Cost-Cutting Measures
6. ADVENTRX Provides Update on Strategic Transaction Process
7. ADVENTRX Announces Further Cost-Cutting Measures
8. ADVENTRX Exploring Strategic Options
9. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
10. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
11. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
(Date:9/18/2014)... /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ) ... separate underwritten offerings of 10,000,000 shares of its Common ... per share, for expected gross proceeds of $20 million ... Stock at a price to the public of $2,000.00 ... Each share of Series A Convertible Preferred Stock is ...
(Date:9/18/2014)... diseases that afflict skeletal growth through abnormalities in ... fetal stage and is caused by genetic mutations. ... factor receptor 3 (FGFR3) has been associated with ... a skeletal dysplasia that cause serious respiratory problems ... (ACH), which causes stunted growth and other complications ...
(Date:9/18/2014)... memory device for computing may have just taken an ... New York led by chemist Stephen O,Brien have discovered ... properties. , Combining both properties is very exciting scientifically ... for the devices that might ultimately be designed, in ... a single material, however, has proved difficult until now. ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Oxides discovered by CCNY team could advance memory devices 2
... , , , , , , ... 11/1999 , , , , , , , ... Cell line , COS-1, monkey, kidney, , ... pEGFP-N1 (in bidistilled H 2 O), , , ...
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.510 12/2001 , ... , , , , , ... , Cell type , Bacteria, ...
... , , , , , , ... 915.032 03/2000 , , , , , , ... Cell line , BW 5147, mouse lymphoma T-cell line, ... Plasmid pEGFP-N1 (in bidistilled H 2 O), , ...
Cached Biology Technology:COS-1 2Corynebacterium glutamicum 2BW 5147 2
(Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
(Date:9/18/2014)... manipulate spoken language is unique to humans. "The genetic ... of human evolution to make this possible are largely ... now have," says Wolfgang Enard, Professor of Anthropology and ... the molecular biological basis of language Enard has now ... latest study, undertaken in collaboration with scientists at several ...
(Date:9/18/2014)... seem to be cheerful, happy-go-lucky characters, so you might ... life. , In fact some dogs are distinctly ... Sydney shows. , "This research is exciting because ... objectively and non-invasively. It offers researchers and dog owners ... that changes," said Dr Melissa Starling, from the Faculty ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3
... California, Davis, have invented a superthin "nanoglue" that could ... itself (say, semiconductor wafers) would break before the glue ... He and his fellow researchers have filed a provisional ... two surfaces. Pan,s nanoglue, which conducts heat and can ...
... As scientists continue the hunt for energy sources that ... amount of valuable farmland is being used to produce ... sources are renewable, economists and ecologists fear that diverting ... drive up costs. Now, Prof. Avigdor Abelson ...
... addressing the major challenges facing humanity in the 21st Century, ... Perspective published in The Plant Cell , the two ... to transforming plant biology in order to meet human needs. ... the biosphere, provide food and materials used by humans, and ...
Cached Biology News:Is seaweed the future of biofuel? 2The future of plant science a technology perspective 2
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
NEWBORN CALF SERUM AND PLASMA...
Synaptic Vesicle I Sampler Kit 10g each...
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Biology Products: